DE69942708D1 - Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten - Google Patents

Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten

Info

Publication number
DE69942708D1
DE69942708D1 DE69942708T DE69942708T DE69942708D1 DE 69942708 D1 DE69942708 D1 DE 69942708D1 DE 69942708 T DE69942708 T DE 69942708T DE 69942708 T DE69942708 T DE 69942708T DE 69942708 D1 DE69942708 D1 DE 69942708D1
Authority
DE
Germany
Prior art keywords
virus
concentration
methods
containing compositions
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942708T
Other languages
English (en)
Inventor
Andreas Frei
Henry K H Kwan
Varda E Sandweiss
Gary J Vellekamp
Pui-Ho Yuen
Laureano L Bondoc Jr
Frederick William Porter Iv
John Chu-Tay Tang
Peter Ihnat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE69942708D1 publication Critical patent/DE69942708D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69942708T 1998-02-17 1999-02-12 Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten Expired - Lifetime DE69942708D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US7964398A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
DE69942708D1 true DE69942708D1 (de) 2010-10-07

Family

ID=26698472

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69933433T Expired - Lifetime DE69933433T2 (de) 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
DE69936948T Expired - Lifetime DE69936948T2 (de) 1998-02-17 1999-02-12 Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
DE69942708T Expired - Lifetime DE69942708D1 (de) 1998-02-17 1999-02-12 Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69933433T Expired - Lifetime DE69933433T2 (de) 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
DE69936948T Expired - Lifetime DE69936948T2 (de) 1998-02-17 1999-02-12 Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten

Country Status (25)

Country Link
EP (4) EP1054955B1 (de)
JP (3) JP4358434B2 (de)
KR (5) KR100912362B1 (de)
CN (2) CN100374551C (de)
AR (3) AR020054A1 (de)
AT (3) ATE371020T1 (de)
AU (1) AU757976B2 (de)
BR (1) BR9908015A (de)
CA (2) CA2320419C (de)
CO (1) CO4820440A1 (de)
DE (3) DE69933433T2 (de)
DK (1) DK1054955T3 (de)
ES (2) ES2272053T3 (de)
HK (3) HK1028416A1 (de)
HU (1) HU226015B1 (de)
ID (1) ID28298A (de)
IL (2) IL137510A0 (de)
MY (1) MY141641A (de)
NO (1) NO20004104L (de)
PE (1) PE20000265A1 (de)
PL (1) PL197747B1 (de)
PT (1) PT1054955E (de)
SK (1) SK11842000A3 (de)
TW (1) TWI232107B (de)
WO (1) WO1999041416A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE550429T1 (de) 1996-11-20 2012-04-15 Crucell Holland Bv Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP1977764A1 (de) * 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Adenovirusformulierung für die Gentherapie
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
AU2002218535A1 (en) * 2000-12-12 2002-06-24 Japan Tobacco Inc. Pharmaceutical composition containing an active with a hemolytic action and a surfactant
CA2469623C (en) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
PL371261A1 (en) * 2002-01-18 2005-06-13 Schering Aktiengesellschaft Stabilized formulations of adenovirus
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
JP2008518632A (ja) 2004-11-03 2008-06-05 イントロゲン セラピューティックス， インコーポレイテッド アデノウイルスベクターの製造および精製のための新規方法
WO2006065827A2 (en) 2004-12-13 2006-06-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
EP1974044B1 (de) 2005-12-12 2011-01-26 CANJI, Inc. Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
PL2007883T3 (pl) * 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
MX2011004292A (es) 2008-11-03 2011-05-31 Crucell Holland Bv Metodo para la produccion de vectores adenovirales.
HUE057606T2 (hu) 2009-05-02 2022-05-28 Genzyme Corp Génterápia neurodegeneratív rendellenességekre
EA023816B1 (ru) 2010-02-15 2016-07-29 Круселл Холланд Б.В. СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26
WO2012038367A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
EA201390810A1 (ru) 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
KR102023207B1 (ko) 2010-12-02 2019-11-25 온콜리틱스 바이오테크 인코포레이티드 동결건조 바이러스 제형
KR102151890B1 (ko) * 2011-04-29 2020-09-03 온콜리틱스 바이오테크 인코포레이티드 겔 침투 크로마토그래피를 이용한 바이러스의 정제방법
AU2013231423B2 (en) 2012-03-12 2018-10-04 Janssen Vaccines & Prevention B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CN104334188B (zh) 2012-03-22 2016-08-24 克鲁塞尔荷兰公司 抗rsv疫苗
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EA039803B1 (ru) 2013-04-25 2022-03-15 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv до слияния
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
EP3149022A4 (de) * 2014-05-28 2018-01-10 Agency for Science, Technology and Research Virusreduktionsverfahren
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
EA035909B1 (ru) 2015-07-07 2020-08-31 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv до слияния
JP7088841B2 (ja) 2016-04-05 2022-06-21 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された可溶性融合前ｒｓｖ ｆタンパク質
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
EP3464331B1 (de) 2016-05-30 2020-10-28 Janssen Vaccines & Prevention B.V. Stabilisierte präfusionierte rsv-f-proteine
BR112018075969A2 (pt) 2016-06-20 2019-04-02 Janssen Vaccines & Prevention B.V. promotor bidirecional potente e equilibrado
EP3484506A1 (de) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv-impfstoffe
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3624844A1 (de) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Verfahren und zusammensetzungen zur induzierung schützender immunität gegen rsv-infektionen
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
US20220267796A1 (en) * 2019-06-28 2022-08-25 Takeda Pharmaceutical Company Limited Adeno-associated virus purification methods
BR112022014808A2 (pt) 2020-01-31 2022-09-20 Beth Israel Deaconess Medical Ct Inc Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
JP2024509756A (ja) 2021-02-19 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前ｒｓｖ ｆｂ抗原
CN115989321A (zh) * 2021-08-17 2023-04-18 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (de) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
CA2723040A1 (en) 1999-08-19
CO4820440A1 (es) 1999-07-28
EP1741777B1 (de) 2010-08-25
PL197747B1 (pl) 2008-04-30
WO1999041416A2 (en) 1999-08-19
KR100912362B1 (ko) 2009-08-19
AU757976B2 (en) 2003-03-13
ATE341614T1 (de) 2006-10-15
CN100374551C (zh) 2008-03-12
CN101164623B (zh) 2012-11-14
DK1054955T3 (da) 2007-01-15
KR20010072547A (ko) 2001-07-31
JP4358434B2 (ja) 2009-11-04
ID28298A (id) 2001-05-10
BR9908015A (pt) 2001-04-24
PE20000265A1 (es) 2000-04-25
KR20080065614A (ko) 2008-07-14
HK1097413A1 (en) 2007-06-22
EP1526174A2 (de) 2005-04-27
DE69933433T2 (de) 2007-08-23
DE69936948D1 (de) 2007-10-04
EP1526174B1 (de) 2007-08-22
PL342847A1 (en) 2001-07-16
ES2272053T3 (es) 2007-04-16
CA2320419A1 (en) 1999-08-19
JP2006166925A (ja) 2006-06-29
MY141641A (en) 2010-05-31
HUP0100670A3 (en) 2003-10-28
KR100918187B1 (ko) 2009-09-22
CN1297478A (zh) 2001-05-30
EP1526173A2 (de) 2005-04-27
PT1054955E (pt) 2007-01-31
ATE371020T1 (de) 2007-09-15
HK1073481A1 (en) 2005-10-07
TWI232107B (en) 2005-05-11
KR20090127947A (ko) 2009-12-14
AR063314A2 (es) 2009-01-21
ATE478945T1 (de) 2010-09-15
EP1054955B1 (de) 2006-10-04
DE69933433D1 (de) 2006-11-16
HUP0100670A2 (hu) 2001-06-28
KR100991683B1 (ko) 2010-11-04
NO20004104D0 (no) 2000-08-16
KR101018992B1 (ko) 2011-03-07
IL137510A (en) 2012-10-31
JP2002503484A (ja) 2002-02-05
KR20090038927A (ko) 2009-04-21
EP1526173B1 (de) 2012-11-21
IL137510A0 (en) 2001-07-24
CN101164623A (zh) 2008-04-23
KR20080065615A (ko) 2008-07-14
AU2653899A (en) 1999-08-30
AR063315A2 (es) 2009-01-21
ES2290613T3 (es) 2008-02-16
SK11842000A3 (sk) 2001-05-10
EP1526174A3 (de) 2005-08-31
HK1028416A1 (en) 2001-02-16
CA2320419C (en) 2011-02-08
JP2010213727A (ja) 2010-09-30
KR100862169B1 (ko) 2008-10-09
EP1526173A3 (de) 2005-08-10
WO1999041416A3 (en) 1999-11-18
DE69936948T2 (de) 2008-05-15
EP1054955A2 (de) 2000-11-29
EP1741777A1 (de) 2007-01-10
HU226015B1 (en) 2008-02-28
AR020054A1 (es) 2002-04-10
NO20004104L (no) 2000-10-17

Similar Documents

Publication Publication Date Title
DE69942708D1 (de) Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
DE69737793D1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
DE69837703D1 (de) Methoden zum nachweis und zur analyse von virus
DE19882430T1 (de) Korrektur von Emissions-Kontamination und Totzeitverlust
DE60035497D1 (de) Verfharen zur konservierung von viren und mycoplasma
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE69838728D1 (de) Methoden und zusammensetzungen zum wirksameren abfangen von sauerstoff
DE69925820D1 (de) Zubereitungen zur stabilisierung von peg-interferon alpha konjugaten
NO971495D0 (no) Svekkede virus og fremgangsmåte til deres fremstilling
DE69933121D1 (de) Methode, reagent und testsatz zur typisierung des genoms von papillomavirus
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE29808006U1 (de) Sprühvorrichtung zur Behandlung von Schnitt- und Fräskanten
ATE253578T1 (de) Oxazinochinolone zur behandlung von viralen infektionen
DE69002558D1 (de) Zusammensetzungen und methoden zur verhinderung von inkrustierungen.
DE69821053D1 (de) Verfahren zur Herstellung von 2,2,6,6-Tetramethyl-4-piperidyl-Gruppen enthaltenden Polytriazinen
DE60200713D1 (de) Zusammensetzung enthaltend getrocknetes Vollei zur Behandlung von Hepatitis
DE59905059D1 (de) Verfahren zur Herstellung von Hydroxyethylcyclohexanen und Hydroxyethylpiperidinen
ATE295182T1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
DE3777022D1 (de) Verfahren und praeparat zur inaktivierung von viren.
DE69428610D1 (de) Methoden zur kultivierung von infektiösem laryngotracheitis virus und von "egg-drop-syndrome" verursachendem virus
ATA4812000A (de) Mittel zur behandlung von hepatitis c
ATE255594T1 (de) Hepatitis b inhibitoren
DE59813114D1 (de) BK-RiV-Präparate zur Behandlung von proliferativen Zellerkrangungen
DE60008697D1 (de) Verfahren zur Herstellung von 4-(P-methoxyphenyl)-2-amino-butane und Insektizide
DE60114532D1 (de) Verfahren zur Herstellung von optisch activem 1H-3-Aminopyrrolidin und Derivaten davon